Making the case for embedding commercial thinking — Target Product Profile, payer messaging, and HCP segmentation — during Phase 3 trials, not after approval.
Executive Summary (TL;DR)
The Structural Blind Spot: Most pharmaceutical companies treat Phase 3 as a scientific exercise and Phase 0 commercialisation as a post-approval problem. That sequencing is the primary reason successful trials produce underperforming launches.
The Commercial Imperative:The Target Product Profile, label claim decisions, patient population framing, and endpoint selection made during Phase 3 are commercial decisions — and they should be shaped by commercial intelligence from the moment the trial protocol is written.
The Competitive Advantage: Organisations that embed early HCP segmentation, payer messaging frameworks, and evidence generation strategy into their Phase 3 design consistently achieve faster formulary listings, stronger launch uptake, and more durable market positions than those that begin commercial planning at approval.
Pharma & Life Sciences Practice • Brand Strategy Intelligence
Fig 1. A pharma product launch that survives the market is built on pre-approval alignment — not post-approval improvisation.
There is a persistent and expensive myth embedded in the structure of pharmaceutical R&D: that Phase 3 approval marks the starting line for commercial strategy. In reality, treating regulatory approval as the starting line means the race is already lost — the job of the commercial team must begin when clinical development begins, not when it ends. Under this model, Phase 3 is a scientific exercise — endpoints are chosen for approvability, patient populations are selected for statistical power, and comparators are defined by what the agency will accept. Commercial strategy waits in an adjacent room until the approval letter arrives.
The market does not honour that separation. Every decision made in the Phase 3 protocol — the primary endpoint, the patient subgroup definition, the comparator arm, the duration of treatment — is also a commercial decision. It defines what the product can claim on its label, which patients it can reach, how payers will assess its value, and which physicians will have the clinical rationale to prescribe it. Companies that recognise this early build products that launch. Companies that do not build products that stall.
The approval-first model is not irrational — it emerged from a regulatory environment in which getting to market was the dominant challenge. For decades, the primary constraint on a new drug was whether it could clear the agency’s bar for safety and efficacy. Commercial viability was, by necessity, a secondary concern.
That constraint has inverted. In most major therapy areas today, regulatory approval is achievable for products that meet minimum efficacy thresholds. The genuine commercial challenge is differentiation — demonstrating to payers, prescribers, and health systems that a new product offers meaningful clinical or economic value over existing treatment options. And the data required to make that case is generated in the clinical trial, not after it.
When commercial strategy begins at approval, the clinical development team has already locked in the endpoints, the patient population, and the comparators. The commercial team inherits a clinical dataset built for regulatory acceptance and must construct a market access story, an HCP value message, and a payer evidence package from data that was never designed with those purposes in mind. The result is launch messaging that feels misaligned with prescriber needs, HEOR submissions that lack the real-world relevance payers require, and label claims that are technically approved but commercially narrow.
The Target Product Profile is formally defined as a regulatory planning tool — a prospective summary of what a drug sponsor intends to demonstrate about a product’s safety and efficacy to secure approval. In practice, the TPP is one of the most powerful commercial strategy documents in pharmaceutical development, and most companies use it only for the former purpose.
A commercially intelligent TPP goes beyond defining minimum and ideal regulatory endpoints. It answers the questions that will determine commercial success: What differentiated clinical claim will motivate prescribers in the target therapeutic area to switch patients from current standard of care? What efficacy or safety profile would secure a preferred formulary position with the top five payer organisations in the target market? What patient subgroup — if demonstrably identified by biomarker or clinical characteristic — would allow the product to command premium pricing and resist biosimilar erosion?
These questions belong in the TPP from the first draft. When they are included, the clinical development team can design endpoints, subgroup analyses, and data collection instruments that generate the commercial evidence the launch will require. When they are excluded, the commercial team spends the post-approval period trying to extract answers from a dataset that was never asked the right questions.
"Products with a commercially co-developed Target Product Profile — one that integrates payer value thresholds and HCP differentiation messaging from the protocol design stage — are 1.8× more likely to achieve formulary access within 90 days of approval than those built on a regulatory-only TPP."
Payer organisations in India, Southeast Asia, and global markets increasingly require a specific category of evidence that neither regulatory submissions nor standard Phase 3 datasets reliably provide: health economic data that demonstrates the product’s value relative to the actual cost burden of the disease in real clinical settings. This evidence — the domain of Health Economics and Outcomes Research — cannot be retrospectively constructed from a regulatory trial. It must be designed in.
During Phase 3, the evidence generation strategy should be running in parallel with the clinical development programme. This means embedding patient-reported outcome instruments that capture quality of life, productivity, and caregiver burden alongside the primary efficacy endpoints. It means prospectively collecting resource utilisation data — hospitalisations, outpatient visits, concomitant medications — that will form the basis of a cost-effectiveness model. And it means designing observational substudies or registry linkages that will generate the real-world evidence payers are increasingly prioritising over randomised controlled trial data alone.
Payer messaging frameworks — the structured arguments that will be used in formulary submissions, value dossiers, and health technology assessments — should be drafted during Phase 3, updated at interim analysis, and finalized at data lock. By the time regulatory approval is granted, the market access team should be holding a pre-built evidence package ready for immediate submission, not beginning the process of assembling one.
One of the most consequential commercial investments a pharmaceutical company can make during Phase 3 is mapping the prescriber landscape before the product has a label. Early HCP segmentation — identifying which physician archetypes will be the first adopters, the early majority, and the sceptical late adopters of the new therapy — allows the commercial team to design a launch sequence that concentrates resources where the probability of early prescribing uptake is highest.
This segmentation is not a promotional exercise. It is a scientific and commercial intelligence process. Which specialist societies are most influential in the target therapeutic area? Which academic centres are running competitive clinical trials that will shape the prescriber community’s prior expectations of this class of drug? Which investigators in your own Phase 3 trial represent the prescribing networks that will generate first-wave adoption at launch?
KOL engagement that begins during Phase 3 — through investigator meetings, advisory boards, and scientific exchange programmes — creates a layer of clinical familiarity and institutional awareness that cannot be manufactured in the 90 days before launch. Prescribers who have been part of the evidence generation conversation do not need to be persuaded of the clinical rationale at the detail visit. They have already formed a view, and in most cases, a favourable one.
Every Phase 3 protocol contains commercial decisions that the clinical development team may not recognise as such. The choice of primary endpoint determines what the label can say. The choice of patient population determines who the label can reach. The choice of comparator determines what the product can be positioned against in promotional materials and payer submissions. These are not neutral scientific choices — they are the architecture of the commercial opportunity.
Label claim optimisation is the discipline of ensuring that the clinical design choices made in Phase 3 are aligned with the commercial claims that will differentiate the product in the market. It requires the commercial, medical affairs, and regulatory teams to work from a shared document — ideally the commercially co-developed TPP — and to stress-test endpoint and population choices against the following commercial questions: Does the primary endpoint translate into a claim that prescribers will find meaningful? Does the patient population definition allow the field force to identify and target addressable patients efficiently? Does the comparator choice allow a clinically and commercially credible differentiation story?
When these questions are asked during protocol design rather than after data lock, the answers can still influence the trial. When they are asked at approval, the label is already written.
Phase 3 is not a scientific waiting room for the commercial team. It is the single most consequential commercial investment a pharmaceutical company makes — and the evidence, positioning, and stakeholder relationships built during that period will determine whether the launch succeeds or merely achieves regulatory approval.
The organisations that reject the “Phase 3 as starting line” myth and integrate commercial strategy into clinical development — through a commercially intelligent TPP, an embedded evidence generation programme, early HCP segmentation, and label claim optimisation — launch with assets the market is already prepared to receive. Those that maintain the approval-first model launch into a market they are only beginning to understand at the moment they most need to lead it.
OneAlphaMed’s Brand Strategy & Product Launch practice works with pharmaceutical companies from Phase 3 protocol design through post-approval commercialisation — ensuring that clinical development and commercial strategy move together from the first day. Learn more at onealphamed.com/brand-strategy-product-launch/
Phase 3 commercial strategy refers to the deliberate integration of commercial planning — including payer messaging, HCP segmentation, evidence generation design, and label claim optimisation — into the clinical trial phase of drug development. Rather than waiting for regulatory approval to begin commercial planning, organisations embed these workstreams into the trial protocol and data collection process to accelerate post-approval launch readiness.
The Target Product Profile defines what a drug will claim on its label and for which patients. These determinations directly shape which prescribers can use the product, how payers will assess its value, and what differentiation story the commercial team can build at launch. A TPP developed with commercial input — not just regulatory input — ensures the clinical trial is designed to generate the evidence the market will require, not only the evidence the agency will accept.
Payer engagement should begin during Phase 3, at minimum 18–24 months before anticipated regulatory approval. Early engagement allows pharmaceutical companies to understand the specific evidence requirements of target formulary committees, design HEOR studies that capture the data payers need, and draft the value dossier in parallel with the regulatory submission — dramatically accelerating formulary listing timelines post-approval.
+91 9811660635
info@onealphamed.com
2414, Ground Floor, Aravali Vihar, Sector 49 Faridabad, Haryana – 121001 India
Copyright © 2026 OneAlphaMed. All Rights Reserved.
